Tremfyam guselkumab

Showing 1 posts of 1 posts found.

janssen_latest_logo_on_sign

Janssen’s Tremfya shows long-term efficacy in moderate to severe plaque psoriasis

February 19, 2018
Research and Development, Sales and Marketing Janssen, Tremfyam guselkumab, pharma, plaque psoriasis, psoriasis

Janssen has unveiled new Phase 3 trial data for its IL-23 inhibitor Tremfya (guselkumab), demonstrating that the drug was able …

Latest content